What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China

Frontiers in Pharmacology

Yijiang Yu¹  Yingyao Chen²  Shimeng Liu²  Zhigang Liu³  Jing Liu³  Chengxiang Tang⁴  Lei Si⁶ 

[1] Huai’an Hospital of Traditional Chinese Medicine, Huai'an, China;NHC Key Laboratory of Health Technology Assessment (Fudan University), Shanghai, China;School of Management, Hainan Medical University, Haikou, China;School of Public Administration, Guangzhou University, Guangzhou, China;School of Public Health, Fudan University, Shanghai, China;The George Institute for Global Health, UNSW Sydney, Kensington, NSW, Australia;

关键词: best-worst scaling;    patient preferences;    type 2 diabetes mellitus;    second-line antihyperglycemic medications;    China;   

DOI  :  10.3389/fphar.2021.802897

来源: DOAJ

【 摘 要 】

Objective: To estimate patient preferences for second-line antihyperglycemic medications in China.Methods: A face to face survey with the best-worst scaling (BWS) choices was administered in patients with diagnosed type 2 diabetes mellitus (T2DM). Study participants were asked to indicate which attribute they valued most and which attribute they valued least in 11 choice sets, each of which consisted of five alternatives out of 11 antihyperglycemic medication-specific attributes (treatment efficacy, weight change, hypoglycemic events, gastrointestinal side effects, cardiovascular health, urinary tract infection and genital infection side effects, edema, mode of administration, bone fracture, dosing frequency and out-of-pocket cost). A counting approach, a conditional logit model, and K-means clustering were used to estimate the relative importance of items and preference heterogeneity.Results: A total of 362 participants were included with a mean age of 63.6 (standard deviation: 11.8) years. There were 56.4% of participants were women, and 56.3% being diagnosed with diabetes for at least 5 years. Efficacy, cardiovascular health and hypoglycemic events were valued most, while dosing frequency, mode of administration and bone fracture were valued least. The K-means clustering further showed preference heterogeneity in out-of-pocket cost across the participants.Conclusion: Our study suggests that treatment efficacy, cardiovascular health and hypoglycemic events are valued most by Chinese patients with T2DM when selecting second-line antihyperglycemic medications. The study improves the understanding of patients’ preferences for second-line antihyperglycemic medications in China.

【 授权许可】

Unknown